Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Benton Loggains

Physician Assistant Fort Smith, AR Physician Assistant

NPI 1891763165 CMS profile 11252721

3501 W E Knight Drive, Fort Smith, AR 72903

Open in the dashboard

General payments

$39,495

180 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benton Loggains of Fort Smith, AR is reported in the CMS Open Payments database as having received $39,495 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,616 45
2024 General $11,482 43
2023 General $6,616 28
2022 General $1,758 23
2021 General $6,023 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benton Loggains
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Benton Loggains were reported at $13,616. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Benton Loggains Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $6,023 $132 $37–$438 $132
2022 $1,758 $155 $48–$522 $149
2023 $6,616 $167 $52–$557 $160
2024 $11,482 $178 $55–$600 $164
2025 $13,616 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $38,720 145 payments
  2. Radius Health, Inc. $257 14 payments
  3. Eisai Inc. $123 1 payment
  4. Ferring Pharmaceuticals Inc. $110 5 payments
  5. Kowa Pharmaceuticals America, Inc. $74 4 payments
  6. Bioventus LLC $46 3 payments
  7. Zimmer Biomet Holdings, Inc. $41 1 payment
  8. KCI USA, Inc $32 2 payments
  9. Vertex Pharmaceuticals Incorporated $24 1 payment
  10. Abbott Laboratories $22 1 payment
  11. Other $46 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $33,775 33 payments
  2. Food and Beverage $3,093 134 payments
  3. Travel and Lodging $2,612 11 payments
  4. Education $16 2 payments
Products named General payments · program years 2021–2025
  1. EVENITY $31,542 130 payments
  2. Prolia $7,826 75 payments
  3. Tymlos Endocrinology $152 9 payments
  4. Dayvigo $123 1 payment
  5. EUFLEXXA $110 5 payments
  6. SEGLENTIS $59 3 payments
  7. Tymlos Endocrinology $49 2 payments
  8. Gel-One Cross-linked Hyaluronate Spine $41 1 payment
  9. Gel-One Cross-linked Hyaluronate Hips $41 1 payment
  10. VISCO-3 sodium hyaluronate $41 1 payment
  11. Other $202 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

532

Median for Physician Assistant: 241

Drug cost

$102,316

Median for Physician Assistant: $4,110

Branded share of claims

29.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Forteo Teriparatide Brand 17 $60,216
Teriparatide Generic 13 $37,452
Ultra-Fine Mini Pen Needle Pen Needle, Diabetic Brand 30 $1,425
Risedronate Sodium Generic 20 $889
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 97 $601
Alendronate Sodium Generic 121 $553
Gabapentin Generic 78 $487
Meloxicam Generic 63 $206
Baclofen Generic 26 $177
Methylprednisolone Generic 21 $138

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$229,014

Of which drugs: $140,679

Medicare patients

754

Average age 76

Services billed

10,928

617 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 70%
Osteoporosis 64%
Chronic kidney disease 32%
Ischemic heart disease 30%
Depression 30%
Heart failure 23%
Diabetes 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 96 5,820 $110,400
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 43 64 $25,878
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 215 2,624 $203

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $11,234
$11,234 — —
Prolia
  • Amgen Inc. $63
$63 — 5,820
Tymlos
  • Radius Health, Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record